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Objectives. This study was performed to determine the optimal 
position for the proximal electrode in a two-electrode transvenous 
defibrillation system. 
Background. Minimizing the energy required to defibrillate the 
heart has several potential advantages. Despite the increased use 
of two-electrode transvenous defibrillation systems, the optimal 
position for the proximal electrode has not been systematically 
evaluated. 
Methods. Defibrillation thresholds were determined twice in 
random sequence in 16 patients undergoing implantation of a 
two-lead transvenous defibrillation system; once with the proxi- 
mal electrode at the right atrial-superior vena cava junction 
(superior vena cava position) and once with the proximal elec- 
trode in the left snbclavian-innominate vein (innominate vein 
position). 
Results. The mean (-+SD) defibrillation threshold with the 
proximal electrode in the innominate vein position was signifi- 
cantly lower than with the electrode in the superior vena cava 
position (13.4 _+ 5.7 J vs. 16.3 - 6.6 J, p = 0.04). Defibrillation 
threshold with the proximal electrode in the innominate vein 
position was lower or equal to that achieved in the superior vena 
cava position in 75% of patients. In patients with normal heart 
size (cardiothoracic ratio _<0.55), the improvement in defibrilla- 
tion threshold with the proximal electrode in the innominate vein 
position was more significant han in patients with an enlarged 
heart (innominate vein 13.0 -+ 6.5 J vs. superior vena cava 17.9 -+ 
5.1 J, p < 0.01). In patients with an enlarged heart, no difference 
between the two sites was observed (innominate vein 13.9 _+ 4.5 J 
vs. superior vena cava 13.6 -+ 8.3 J, p = NS). 
Conclusions. During implantation of a two-lead transvenous 
defibrillation system, positioning the proximal defibrillation elec- 
trode in the subclavian-innominate vein will lower defibrillation 
energy requirements in the majority of patients. 
(J Am CoU Cardiol 1996;27:90-4) 
Advances in defibrillation lead technology have led to the 
development of single- and two-lead transvenous ystems. 
Single-lead systems defibrillate by means of a right ventricular 
and proximal electrode with a fixed interelectrode distance (1). 
In contrast, the proximal electrode in a two-lead system may be 
variably positioned in the superior vena cava, the innominate 
vein or the coronary sinus, a feature of potential value in 
obtaining satisfactory defibrillation thresholds at time of im- 
plantation (2-4). 
In two-lead transvenous systems, the optimal position of the 
proximal electrode to provide lower defibrillation energy re- 
quirements is unknown. Therefore, the present study was 
designed to prospectively compare defibrillation thresholds 
achieved at defibrillator implantation using biphasic shock 
waveforms and two different proximal electrode positions. 
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Methods  
Patients. Sixteen patients with a history of ventricular 
fibrillation or sustained ventricular tachycardia, who were 
undergoing implantation of an implantable cardioverter- 
defibrillator (Medtronic model 7219D) and transvenous leads 
at the Oregon Health Sciences University or the University of 
Minnesota, participated in the study (Table 1). Written informed 
consent was obtained from each patient. The protocol was 
approved by the institutional review boards at both universities. 
Antiarrhythmic therapy was discontinued for five elimina- 
tion half-lives before implantation, with the exception of four 
patients with long-term amiodarone therapy. 
Defibrillator implantation. All patients underwent defi- 
brillator implantation under general anesthesia. A 10.5F active 
fixation lead (Medtronic model 6966) with bipolar sensing and 
pacing electrodes at the tip and a 5.0-cm distal defibrillation 
electrode was inserted through the left subclavian or cephalic 
vein and positioned under fluoroscopy in the right ventricular 
apex. Acceptable pacing and sensing characteristics were re- 
quired before proceeding. A second 6.5F lead with a 5.0-cm 
defibrillation electrode (Medtronic model 6963) was then 
inserted through the left subclavian or cephalic vein and 
positioned in either the superior vena cava or innominate vein. 
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Table 1. Clinical Characteristics of 16 Study Patients 
Age (yr) 59 + 14 
Male 14 
Female 2 
Presenting rhythm 
Ventricular fibrillation 7 
Ventricular tachycardia 9 
Etiology 
Coronary artery disease 12 
Hypertrophic cardiomyopathy 1 
Valvular heart disease 1 
Dilated cardiomyopathy 1 
Primary. electrical disease 1 
EF (%) (n = 15) 38 z 13 
Preserved left ventricular 6 
function (EF >40%) 
Moderate l ft ventricular l0 
dysfunction (EF <40%) 
Data presented are mean value _~ SD or number of patients. EF = ejection 
fraction. 
Two positions of the proximal electrode were tested in each 
patient. For the innominate vein position (Fig. 1), the proximal 
electrode was positioned in the innominate and subclavian 
veins, with the tip of the lead positioned between the right 
vertebral border and the spinous process. For the superior 
vena cava position (Fig. 2), the tip of the lead was positioned 
at the junction of the superior vena cava and the right atrium. 
During threshold testing, ventricular fibrillation was in- 
duced with a synchronized T wave shock and observed for 10 s 
before defibrillation. Endocardial defibrillation shocks were 
delivered by an external defibrillator (Medtronic model 5358) 
utilizing biphasic waveforms of 65% tilt. If the endocardial 
shock failed to terminate ventricular fibrillation, sinus rhythm 
was immediately restored by transthoracic defibrillation. 
The first proximal electrode position tested was randomly 
chosen to minimize any potential effects of multiple fibrillation 
inductions and defibrillation shocks. Defibrillation thresholds 
were determined using a step-down protocol starting at 16 J. If 
successful, subsequent shocks were tested at 13, 10, 7 and 4 J 
or until defibrillation failed. The defibrillation threshold was 
defined as the last energy delivery successful in restoring the 
patient's native or paced rhythm. If the initial 164 shock failed, 
20- and 24-J shocks were tested. If these failed, the defibrilla- 
tion threshold for that position was arbitrarily assigned avalue 
of 28 J. 
Next, the proximal ead was repositioned, and the second 
position was tested using the same step-down protocol as 
previously described. However, to minimize shocks, the initial 
energy tested was the defibrillation threshold of the first 
position. After the defibrillation threshold for the second 
position was obtained, the lead was repositioned to the loca- 
tion yielding the lower defibrillation threshold, and implanta- 
tion protocol was then completed. 
Statistical analysis. For each defibrillation sequence, the 
stored energy, delivered energy, pulse duration and impedance 
were measured, and the delivered leading-edge voltage was 
calculated. Results are expressed as mean value + SD. Com- 
parisons were made using the Student paired test for contin- 
uous variables and the Fisher exact est for categoric variables; 
p -< 0.05 was considered significant. 
Results 
Defibrillation thresholds. The mean defibrillation thresh- 
old (delivered energy) using the innominate vein position was 
13.4 _ 5.7 J. Defibrillation with the proximal electrode in this 
position was successful in all patients (Fig. 3). The mean 
defibrillation threshold using the superior vena cava position 
was 16.3 _+ 6.6 J. In two patients, defibrillation at 24 J was 
unsuccessful with the proximal electrode in the superior vena 
cava position. The difference in defibrillation thresholds at the 
two positions was significant (p = 0.04). The innominate vein 
position yielded the lower defibrillation threshold in nine 
patients. The superior vena cava position yielded lower defi- 
brillation thresholds in four patients, and in three patients the 
defibrillation threshold was the same for both positions. 
Figure 1. Innominate vein position of the proximal 
electrode. The active fixation distal lead is posi- 
tioned in the right ventricular apex, with the distal 
defibrillation electrode adjacent to the intraventric- 
ular septum. The proximal lead is positioned with 
its tip at the right vertebral border. This position 
yields a parallel orientation of the defibrillation 
electrodes with the intraventricular septum and 
base of the heart positioned between the elec- 
trodes. The implantable cardioverter-defibrillator 
is shown implanted in a pectoral position. 
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Figure 2. Right atrial-superior vena cava position. The 
tip of the proximal electrode is positioned at the junction 
of the superior vena cava and right atrium. The defibril- 
lation electrodes are in close proximity and are posi- 
tioned in a perpendicular configuration. 
Similar differences between the innominate vein and supe- 
rior vena cava positions were found at threshold for stored 
energy (14.1 _+ 5.9 and 17.1 _+ 6.4 J, respectively, p = 0.05) and 
calculated leading-edge voltage (476 _+ 102 and 525 _+ 103 V, 
respectively, p = 0.06) (Table 2). 
Because of concern that repeated shocks may have had an 
effect on the defibrillation threshold, the defibrillation thresh- 
olds obtained at the randomly chosen first position were 
compared with those obtained at the second position. The 
defibrillation threshold of the first position tested was 14.8 _+ 
5.2 J compared with 14.8 _+ 7.3 J for the second position. The 
difference was not significant, indicating that defibrillation 
thresholds were dependent on the electrode position and not 
on the sequence of testing. 
There was a significant difference between mean impedance 
measurements at defibrillation threshold for the innominate 
vein versus superior vena cava positions (Fig. 4). The mean 
impedance for the innominate vein position was 68 +_ 8.4 
compared with 55 + 5.7 ohms at the superior vena cava 
position (p = 0.0001). In each case, the lower impedance was 
found in the superior vena cava position. 
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Figure 3. Comparison of the defibrillation thresholds (DFT) obtained 
at the innominate vein and superior vena cava (SVC) positions for 
each patient. The innominate vein position yielded the lower defibril- 
lation threshold in nine patients. The superior vena cava position 
yielded the lower defibrillation threshold in four patients, and in three 
patients the defibrillation threshold was the same for both positions. 
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To determine possible mechanisms by which lower defibril- 
lation thresholds were achieved with the proximal electrode in 
an innominate vein position, analysis was performed compar- 
ing the lead position yielding the lower threshold with the 
presenting rhythm (ventricular tachycardia or fibrillation), 
ejection fraction (>40% or <40%), smoking history (a reflec- 
tion of chronic pulmonary disease), amiodarone therapy and 
the cardiothoracic ratio measured on a standard PA chest 
radiograph (an index of cardiomegaly). 
There was no correlation between optimal lead position 
and baseline variables, with the exception of the cardiothoracic 
ratio (p -- 0.05). The cardiothoracic ratio was found to be 
present in a bimodal distribution, with a ratio of 0.55 differ- 
entiating patients with high versus low ratios (low ratio 0.49 _+ 
0.03 ]eight patients]; high ratio 0.62 _+ 0.05 [six patients]; 
cardiothoracic ratio 0.55 [two patients]). A cardiothoracic ratio 
-<0.55 was associated with the innominate vein electrode 
position providing the lower defibrillation thresholds in 8 of 10 
patients. (The superior vena cava position provided a lower 
defibrillation threshold in one patient, and both positions were 
equivalent in one.) For these 10 patients, the mean defibrilla- 
tion threshold for the innominate vein position was 13.0 _+ 
6.5 J compared with 17.9 _+ 5.1 J for the superior vena cava 
position (p = 0.006, Table 3). In contrast, a cardiothoracic 
ratio >0.55 correlated with a superior vena cava lead position 
providing the lower defibrillation thresholds in three of six 
Table 2. Defibrillation Thresholds and High Voltage Impedance 
Delivered Stored 
Energy Energy Leading-Edge Impedance 
(J) (J) Voltage (V) (ohms) 
lnnominate vein 13.4 + 5.7 14.1 + 5.9 476 _+ 102 68 + 8.4 
position 
SVC position 16.3 _+ 6.6 17.1 + 6.4 525 _+ 103 55 + 5.7 
p value 0.04 0.05 0.06 0.000l 
Data presented are mean value + SD, unless otherwise indicated. SVC = 
superior vena cava. 
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Figure 4. Impedance at the defibrillation threshold for the innominate 
vein and superior vena cava (SVC) positions for each patient. The 
difference inimpedance is significant (p= 0.0001). In each case, the 
lower impedance was found in the superior vena cava position. 
patients. (The innominate vein position provided a lower 
defibrillation threshold in one patient, and both positions were 
equivalent in two.) In these six patients, the mean defibrillation 
threshold for the innominate vein position was 13.9 + 4.5 
compared with 13.6 _+ 8.3 J for the superior vena cava position 
(p = NS). 
Discuss ion  
Transvenous defibrillation represents a significant advance 
in implantable cardioverter-defibrillator echnology, allowing 
easier device implantation, similar efficacy and lower rates of 
morbidity and mortality than that with epicardial lead systems 
(3-6). Reduction of defibrillation thresholds has resulted in 
reduced procedural time, increased numbers of implants with 
transvenous leads only (no subcutaneous patches), implanta- 
tion in the cardiac atheterization laboratory and the develop- 
ment of smaller devices (1,2,7-10). In laboratory and clinical 
protocols, the effects of coil size, lead configuration, lead 
combinations and unipolar defibrillation on defibrillation 
thresholds have been investigated (11-15). 
Defibrillation electrode position. The present study com- 
pared defibrillation thresholds obtained with different posi- 
tions of the proximal electrode in a two-lead transvenous 
system. Despite uniformly higher impedance measurements, 
an innominate vein position of the proximal electrode pro- 
vided reduced efibrillation thresholds compared with a low 
superior vena cava position. More important, in 75% of the 
patients tested, improved or similar defibrillation thresholds 
were demonstrated with the innominate vein position, whereas 
the maximal energy tested failed to achieve defibrillation in 
two patients with the proximal electrode in the superior vena 
cava position. These findings suggest that, in most cases, the 
innominate vein position should be utilized. 
The mechanism by which the innominate vein proximal 
electrode position results in lower defibrillation thresholds may 
be, in part, the result of a more parallel orientation of the 
defibrillation electrodes than that in the low superior vena cava 
position (Fig. 1 and 2). A parallel configuration of the defibril- 
lation electrodes may provide a more uniform voltage gradient 
Table 3. Cardiothoracic Ratio Versus Proximal Electrode Position 
Mean Defibrillation Threshold (J) 
Innominate Vein 
SVC Electrode Electrode 
Position Position 
Cardiothoracic Ratio (mean _+ SD) (mean _+ SD) 
-<0.55 (n = 10) 17.9 _+ 5.1 13.0 + 6.5* 
>0.55 (n = 6) 13.6 _+ 8.3 13.9 + 4.5 
*p = 0.006. SVC = superior vena cava. 
and more myocardial mass between the defibrillation elec- 
trodes than the more perpendicular configuration seen in the 
superior vena cava position (16-18). Additionally, having the 
proximal electrode in the innominate vein may direct the 
current vector posteriorly, incorporating more of the left 
ventricular septum (13,19). 
Anatomic considerations. When the heart size is normal, 
electrode orientation may become ven more important, as is 
seen by the strong correlation between a low cardiothoracic 
ratio and improved defibrillation thresholds with an innomi- 
nate vein proximal electrode position. The cardiothoracic ratio 
was used in the present study as an indication of heart size. 
Eight of 10 patients with normal heart sizes (cardiothoracic 
ratio -<0.55) had improved defibrillation thresholds with the 
proximal electrode in the innominate vein position. With 
preserved heart size, the right atrial-superior vena cava posi- 
tion of the proximal electrode reduces the distance between 
the defibrillation electrodes. This, coupled with the perpendic- 
ular orientation of the electrodes, may allow shunting of 
current between the distal end of the proximal electrode to the 
proximal end of the right ventricular electrode, resulting in a 
more uneven voltage gradient distributed through the myocar- 
dium. In contrast, the proximal electrode in the innominate 
vein position may allow a more uniform voltage gradient and, 
therefore, improved efibrillation efficacy. 
The correlation between heart size and the proximal elec- 
trode position is even more striking when patients with pre- 
served heart size are considered alone (Table 3). For the 10 
patients with a cardiothoracic ratio -<0.55, the mean defibril- 
lation threshold with the proximal electrode in the innominate 
vein was significantly ower than when it was positioned at the 
right atrial-superior vena cava junction. However, in enlarged 
hearts there is an increased istance between the superior vena 
cava position and the right ventricular electrode, which may 
reduce current shunting. In this setting, the differences in 
electrode orientation may not be as important. In the six 
patients with a high cardiothoracic ratio, there was no differ- 
ence in mean defibrillation thresholds between the two proxi- 
mal electrode configurations. 
Conclusions. In a two-lead transvenous defibrillation sys- 
tem using biphasic waveform shocks, an innominate vein 
position of the proximal electrode provided lower defibrillation 
thresholds for most patients. The ability to adjust he position 
of the proximal lead is a potential advantage of two-lead 
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systems. In addition, the findings may be helpful in choosing 
the interelectrode istance in single-lead systems according to 
heart size of the patient. 
On the basis of the results of the present study, the 
following implantation strategy is proposed: For patients with 
preserved heart size (herein defined as a cardiothoracic ratio 
-<0.55), an innominate vein position of the proximal electrode 
should be tested first. If inadequate results are obtained, the 
right atrial-superior vena cava position should be tested before 
the addition of a subcutaneous patch to the system. For 
patients with significantly enlarged hearts, either an innomi- 
nate or right atrial-superior vena cava position may be tried 
first. 
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